Reuters logo
BRIEF-FDA Advisory Committee votes in favor of Pfizer's Mylotarg for acute myeloid leukemia
July 11, 2017 / 8:43 PM / 2 months ago

BRIEF-FDA Advisory Committee votes in favor of Pfizer's Mylotarg for acute myeloid leukemia

July 11 (Reuters) - Pfizer Inc

* FDA Advisory Committee votes in favor of Pfizer‘S Mylotarg (gemtuzumab ozogamicin) for acute myeloid leukemia

* Pfizer Inc - ‍FDA decision on whether or not to approve Mylotarg application is anticipated by September 2017​

* Pfizer - Committee votes 6-1 that mylotarg in combination with chemotherapy has favorable risk:benefit profile for patients with newly-diagnosed cd33-positive aml Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below